Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab combined with high- and low-dose radiotherapy for advanced solid tumors after first-line treatment failure
ChiCTR2500095867Phase 2Not yet recruiting
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in Nonhematologic neoplasms, sponsored by Affiliated Hospital of Jiangnan University. Primary endpoint: overall response rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2500095867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095867.